Medtronic develops, manufactures, and sells medical devices, therapies, and services for many chronic conditions. Key business areas include:
Cardiovascular: pacemakers, defibrillators, stents, heart valves, cardiac ablation, structural heart devices. StockAnalysis+2Medtronic+2
Neuroscience: devices for spinal health, brain modulation, neuromodulation, drug infusion systems, nerve ablation. StockAnalysis+1
Medical Surgical: minimally invasive therapies, monitoring and acute care, endoscopy, surgical tools etc. Medtronic+1
Diabetes: therapies and tech for insulin management, for Type 1 and Type 2 diabetics. Medtronic+1
They treat or have products for 70+ disease / health conditions globally. Medtronic+1
Employees: ~95,000 people worldwide. Medtronic+2IBEF+2
Operational in 150+ countries. Medtronic+2IBEF+2
R&D investment: Billions of dollars (for example, their key facts mention ~$2.7B in R&D investment). Medtronic
Patent portfolio: tens of thousands of active patent matters. Medtronic
Their mission is summed up as "Inspiring the extraordinary", under it the core is:
Alleviate pain. Restore health. Extend life. Medtronic+2Medtronic+2
They emphasize biomedical engineering, doing what they are strong in, reliability & quality, growth in their areas of expertise. Medtronic
They also talk about putting people at the centre (patients, employees) and forging innovation that adapts to lifestyle, data-driven insights, and equity of access. Medtronic+2Medtronic+2
Medtronic has a strong presence in India. Key points:
Operating in India for over 40 years. Medtronic+1
Locations across many major cities: Mumbai, Ahmedabad, Bangalore, Chennai, Cochin, Gurgaon, Hyderabad, Kolkata, New Delhi, Pune, Vadodara. IBEF+1
R&D / Innovation centre: The Medtronic Engineering & Innovation Center (MEIC) in Hyderabad, established 2011. It is their largest R&D center outside the US. Medtronic+1
The Hyderabad centre supports New Product Development, product release, regulatory, quality and global functions. Over 900+ (later ~800‑1000) engineers. Medtronic+1
They also are expanding the R&D footprint in Hyderabad with a ₹3,000 crore (≈ US$350 million) investment, aiming to raise headcount to ~1,500 over next 5 years. The Hindu
Recently, a new Diabetes Global Capability Centre (GCC) has been established in Pune with investment of about $50 million over 5 years to support diabetes business globally (software, analytics, patient financial services etc.). Punekar News+1
Leadership in India: In May 2024, Mandeep Singh Kumar was appointed Vice President & Managing Director for India. Business Standard
Some financial & product details:
Revenue & Income: For FY2025, net income ~$4.662B. Assets ~$91.68B; Equity ~$48.02B. Wikipedia
Their product portfolio is diverse: high tech implantables (pacemakers, defibrillators), monitoring, surgical technology, diabetes devices. Medtronic+1
They run many clinical trials (over 190 active trials per latest key facts) Medtronic
Product Recall: The FDA classified a recall of some of Medtronic’s Pipeline Vantage Embolization devices (used to treat brain aneurysms) as "most serious" following reports of deaths or injuries. Reuters
Diabetes business separation: There are reports/plans that Medtronic may spin off or separate its diabetes division to unlock value, given that business has a more consumer-facing model vs. their more hospital & provider focused units. MarketWatch
Growth in areas: The diabetes unit is one of the fastest growing segments. Their medical devices & surgical volumes have rebounded post‑COVID. Reuters+2Investopedia+2